花旗发表报告指，与云顶新耀举行了最新会议，管理层指导2025年销售额为14亿元，包括Nefecon的10亿元和Xerava的4亿元。而Nefecon已成功纳入国家医保。

（原标题：大行评级丨花旗：上调云顶新耀目标价至40港元 Nefecon销售指引正面） 花旗发表报告指，与云顶新耀举行了最新会议，管理层指导2025年销售额为14亿元，包括Nefecon的10亿元和Xerava的4亿元。而Nefecon已成功纳入国家医保。报告指，云顶新耀今年的主要催化 ...

Nefecon is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass ...

About NEFECON(R) NEFECON(R) is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes ...

About NEFECON(R) NEFECON(R) is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes ...